Gennex Laboratories share news, announcements and annual reports
BSE: 531739Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 30 Oct 2026. Previous close ₹8.96.
30 Oct: open ₹8.91, high ₹9.12, low ₹7.70
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹195 Cr2,248th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 10.60
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.88
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 9.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 7.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.15
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 13,21,688
Gennex Laboratories share news and announcements
553 announcements, routine notices left out, newest first. Page 7 of 12.
Apr 2021
21 Apr · Shareholding for the Period Ended March 31, 2021
Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click ....19 Apr · Compliance Certificate Under Regulation 7(2) & 7(3) Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 Of Gennex Laboratories Limited For The Half Year Ended March 31, 2021
19 Apr · Statement Of Investor Complaints For The Quarter Ended March 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Feb 2021
3 Feb · Board meeting
Meeting on 13 Feb 2021: quarterly results
Jan 2021
19 Jan · Shareholding for the Period Ended December 31, 2020
Shareholding Pattern for the Period Ended December 31, 2020. For more details, kindly Click ....12 Jan · Statement Of Investor Complaints For The Quarter Ended December 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Dec 2020
21 Dec · Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015. - Mr. A S Nageswar Rao, Appointed As An Additional Independent Director Of The Company
21 Dec · Business
18 Dec · Board meeting
Meeting on 21 Dec 20203 Dec · Submission Of Half Yearly Disclosure Under Regulation.23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2015 Of Gennex Laboratories Limited As On September 30, 2020
Nov 2020
12 Nov · Management
3 Nov · Board meeting
Meeting on 12 Nov 2020: quarterly results
Oct 2020
20 Oct · Compliance Certificate Under Regulation 40(9) & 40(10) Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 Of Gennex Laboratories Limited For The Half Year Ended September 30, 2020
19 Oct · Compliance Certificate Under Regulation 7(2) & 7(3) Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 Of Gennex Laboratories Limited For The Half Year Ended September 30, 2020
15 Oct · Shareholding for the Period Ended September 30, 2020
Shareholding Pattern for the Period Ended September 30, 2020. For more details, kindly Click ....13 Oct · Statement Of Investor Complaints For The Quarter Ended September 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Sep 2020
30 Sep · Results
Details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly ....7 Sep · Board meeting
Meeting on 15 Sep 2020: quarterly results
Aug 2020
31 Aug · Submission Of Half Yearly Disclosure On Related Party Transactions Under Regulation.23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2015 Of Gennex Laboratories Limited
27 Aug · Board meeting
Meeting on 3 Sep 2020: annual general meeting
Jul 2020
21 Jul · Board meeting
Meeting on 30 Jul 2020: audited results and quarterly results21 Jul · Shareholding for the Period Ended June 30, 2020
Shareholding Pattern for the Period Ended June 30, 2020. For more details, kindly Click ....20 Jul · Statement Of Investor Complaints For The Quarter Ended June 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Jun 2020
30 Jun · Board meeting
3 Jun · Company Obtained World Health Organisation Good Manufacturing Practices (WHO-G.M.P) Certificate From Drug Control Administration, Government Of Telangana.
May 2020
23 May · Compliance Certificate Under Regulation 40(9) & 40(10) Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 Of Gennex Laboratories Limited For The Half-Year Ended March 31, 2020;
17 May · Compliance Certificate Under Reg.7(3) For The Half Year Ended March 31, 2020.
15 May · Shareholding for the Period Ended March 31, 2020
Shareholding Pattern for the Period Ended March 31, 2020. For more details, kindly Click ....